Table 2 Adverse events occurring in ≥15% of patients in any treatment group

From: Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

 

C1 – Niraparib (n = 25)

C2- Niraparib + Dostarlimab (n = 22)

AE detail

Grade ≥ 3

Total

Grade ≥ 3

Total

Nausea

0 (0%)

14 (56%)

1 (5%)

13 (59%)

Fatigue

5 (20%)

15 (60%)

1 (5%)

11 (50%)

Dyspnoea

0 (0%)

11 (44%)

2 (9%)

13 (59%)

Anaemia

7 (28%)

12 (48%)

6 (27%)

9 (41%)

Constipation

0 (0%)

11 (44%)

0 (0%)

5 (23%)

Dizziness

0 (0%)

6 (24%)

0 (0%)

9 (41%)

Vomiting

0 (0%)

8 (32%)

0 (0%)

8 (36%)

Creatinine increased

0 (0%)

6 (24%)

0 (0%)

7 (32%)

Anorexia

0 (0%)

7 (28%)

0 (0%)

5 (23%)

Cough

0 (0%)

4 (16%)

0 (0%)

7 (32%)

Palpitations

0 (0%)

4 (16%)

0 (0%)

7 (32%)

Platelet count decrease

4 (16%)

5 (20%)

2 (9%)

6 (27%)

Diarrhoea

0 (0%)

4 (16%)

0 (0%)

5 (23%)

Abdominal pain

1 (4%)

5 (20%)

0 (0%)

4 (18%)

Insomnia

0 (0%)

5 (20%)

0 (0%)

4 (18%)

Gastroesophageal reflux

0 (0%)

2 (8%)

0 (0%)

6 (27%)

Headache

0 (0%)

6 (24%)

0 (0%)

2 (9%)

Hypertension

2 (8%)

6 (24%)

1 (5%)

2 (9%)

Neutrophil count decreased

1 (4%)

3 (12%)

3 (14%)

4 (18%)

Hyponatremia

2 (8%)

6 (24%)

0 (0%)

1 (5%)

Back pain

0 (0%)

5 (20%)

0 (0%)

2 (9%)

Bloating

0 (0%)

1 (4%)

0 (0%)

5 (23%)

White blood cell decreased

0 (0%)

4 (16%)

1 (5%)

2 (9%)

Myalgia

0 (0%)

0 (0%)

1 (5%)

5 (23%)

Hypomagnesemia

0 (0%)

4 (16%)

0 (0%)

1 (5%)

  1. Data are represented in n (%). The order of the adverse events follows the total frequency in both cohorts. Generalized muscle weakness and general muscle weakness have been merged.
Back to article page